Enabling scientific advances to positively impact human health
Your genes. Your health.

Yourgene Health plc
Private Investor evening

24 October 2019
Overview of Yourgene Health plc
Yourgene Health
Key commentary

- **International molecular diagnostics group** which develops and commercialises genetic screening products and services in **over 60 territories**
  - First forays into US market via new Yourgene Health Inc entity
- **Proprietary DNA analysis technology** used to develop safer and improved non-invasive screening tests
- **Acquired Elucigene Diagnostics** in April 2019 for an enterprise value of £8.8m
  - Integration proceeding very well, strong cultural alignment and synergy savings >£0.5m
- **Group now has a suite of leading CE-IVD NGS & PCR products** focused on **reproductive health** including non-invasive prenatal screening (NIPT), Cystic Fibrosis and invasive prenatal aneuploidy screening
- Technology agreements with **Thermo Fisher** and **Illumina**, market leaders in NGS and PCR instrumentation
- **Pipeline of new innovative diagnostic solutions** in development for reproductive health and **oncology** clinical segments
  - **DPYD**, the Group’s first oncology product, launched to better screen patients for chemotoxicity
Yourgene Health

By numbers

A leading NIPT test over 99% accurate(1)

67% volume growth year on year

£8.9 million for year ending 2018/19 revenue (45% growth)

£12.5 million pro-forma revenue (2)

Revenues £7.8 million for the six months to 30 September 2019, up 98% from previous year

Sales in over 60 countries

Global partners

(1) Relating to Down’s syndrome, Edwards syndrome and Patau’s syndrome (2) Pro-forma revenue calculated as £8.9m revenue calculated for 12 months to 31 March 2019 for Yourgene Health and £3.6m to 31 December 2018 for Elucigene Diagnostics
Key investment highlights

1. A leading next generation portfolio of NIPT and PCR solutions in large, fast growing markets with quantitative benefits versus standard of care

2. Blue-chip industry partnerships including leading NGS players, Thermo Fisher and Illumina

3. Real commercial momentum, with clean balance sheet

4. In-house development expertise with pipeline of additional complementary products

5. Elucigene is Yourgene’s latest acquisition in a fragmented market that presents opportunity for further consolidation

6. Experienced management team with combined c.20% shareholding and track-record of executing a commercialisation strategy
Elucigene Diagnostics acquisition offers an opportunity to accelerate Yourgene’s future growth strategy

<table>
<thead>
<tr>
<th>2017</th>
<th>2018</th>
<th>2019+</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Building a Global Platform</strong></td>
<td><strong>Positioning for Accelerated Growth</strong></td>
<td><strong>Accelerating Ahead</strong></td>
</tr>
<tr>
<td>✓ Completion of Yourgene Biosciences acquisition</td>
<td>✓ NGS collaborations agreed with Abnova and Coastal Genomics</td>
<td>✓ Major capital and commercial agreement with Thermo Fisher, writing off £12.7m of loans for 9% shareholding in Company</td>
</tr>
<tr>
<td>✓ Increased access to Asia, the world's fastest growing NIPT market</td>
<td>✓ Lyn Rees appointed CEO</td>
<td>✓ High throughput product launched (Sage 32 plex)</td>
</tr>
<tr>
<td>✓ IONA® test validated for Thermo Fisher’s Ion S5 instrument range</td>
<td>✓ Final litigation settlement with Illumina ended three and a half year IP dispute</td>
<td>✓ 82,000 NIPT tests completed in year ended 31 March 2019</td>
</tr>
<tr>
<td>✓ New laboratory partnerships established in Europe, Middle East and Asia</td>
<td>✓ Entered into licence and supply partnership agreement with Illumina</td>
<td>✓ Transformational acquisition</td>
</tr>
<tr>
<td>✓ 24,000 NIPT tests completed in the year ended 31 March 2017</td>
<td>✓ 50,000 NIPT tests completed in the year ended 31 March 2018</td>
<td>✓ Product line expansion with DPYD launched</td>
</tr>
</tbody>
</table>

- Deliver US market entry
  - Regulatory submission for NIPT on Illumina platform
Current and potential future products

Current Product Portfolio

Solutions across the Reproductive Health pathway

Non-Invasive Prenatal Test

Pre-birth

1st Trimester

2nd Trimester

3rd Trimester

Post-birth

Male Factor Infertility

QST*R Pregnancy Loss

Genetic Thrombosis Risk Test

Miscarriage

Invasive Rapid Aneuploidy (QST*R)

Cystic Fibrosis

New Product Roadmap

• Apply successful existing model to additional tests
• Partnering across the value chain
• Diversify into gene analysis
• Inorganic product acquisition

Potential Future Products

• DPYD 5FU chemotoxicity
• CF US version
• PCR development capability
• NGS variants of Elucigene products

NIPT on New Platforms

Geographic variants for CF markers

Extended Reproductive Menu

Additional Oncology Menu

Launched 18 Sept 2019
Business update
H1 Trading update

• £7.8m H1 revenues and on track to hit full year targets
• Revenues showing 98% growth, year on year – organic growth of 56%
• 34% growth rates for UK / Europe
• Cash and cash equivalents as at 30 September 2019 were £4.1m.
• Revenues are showing greater diversity:
  • 20% derived from reproductive health products generated by the acquired Elucigene
  • 17% derived from oncology and research services activities in Asia.
H1 Trading Update
Regional segments

<table>
<thead>
<tr>
<th>Regional segments</th>
<th>6 months to 30 Sept 2019 £m</th>
<th>6 months to 30 Sept 2018 £m</th>
<th>Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>UK</td>
<td>1.1</td>
<td>0.8</td>
<td>+35%</td>
</tr>
<tr>
<td>Europe ex-UK</td>
<td>1.6</td>
<td>0.8</td>
<td>+90%</td>
</tr>
<tr>
<td>International</td>
<td>5.1</td>
<td>2.3</td>
<td>+122%</td>
</tr>
<tr>
<td>Total</td>
<td>7.8</td>
<td>3.9</td>
<td>+98%</td>
</tr>
</tbody>
</table>
### H1 Trading update

#### Product segments

<table>
<thead>
<tr>
<th>Product segments</th>
<th>6 months to 30 Sept 2019 £m</th>
<th>6 months to 30 Sept 2018 £m</th>
<th>Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>NIPT</td>
<td>4.8</td>
<td>3.6</td>
<td>+34%</td>
</tr>
<tr>
<td>Reproductive Health</td>
<td>1.6</td>
<td>0.0</td>
<td>n/a</td>
</tr>
<tr>
<td>Oncology &amp; research</td>
<td>1.4</td>
<td>0.3</td>
<td>+290%</td>
</tr>
<tr>
<td>Total</td>
<td>7.8</td>
<td>3.9</td>
<td>+98%</td>
</tr>
</tbody>
</table>
Integration highlights

- Integrated marketing and range-selling now effective
- Global sales team conference held in July
- £0.5m annualised integration cost synergies identified and implementation underway
- Head office UK property consolidation well advanced
- Registered office changed to Citylabs 1.0
- All departments combined into single management structure
- Process, systems and regulatory harmonisation plan developed for implementation by mid 2020
- First IVD product launched post acquisition (DPYD)
- Integrated manufacturing operations
- Strong cultural alignment
Expanded Global Coverage

Expanding reach
- YH Inc
- Yourgene coverage
- Extra Elucigene coverage
- Development markets

YH Inc
Yourgene
Health

13
DPYD CE- IVD kit and 5-FU chemotoxicity
Pharmacogenomic impact

• **DPD Deficiency** can cause severe and sometimes lethal side effects in patients receiving 5-Fluorouracil (5-FU) chemotherapy used to treat a range of cancers:
  • Colorectal, Gastric, Head and Neck, Breast

• Estimated that 2 million people are treated with 5-FU every year.
  • 10-20% of these patients will be hospitalised because of DPD deficiency (200,000 - 400,000).
  • 0.1-1% of these patients will die as a result of DPD deficiency (2,000 – 20,000).

• DPYD genotyping can identify these patients with DPD deficiency allowing an alternative treatment to be offered. Recommended by The Clinical Pharmacogenetics Consortium (CPIC) guidelines

• Elucigene® DPYD assay can prevent 5-FU associated toxicity:
  • Prevents unnecessary deaths.
  • Reduces the incidence of hospital admissions.
Territory Expansion
USA, China & Japan

- United States remains the largest market for medical devices, at more than USD $150 billion
- Yourgene Health Inc established
- First US commercial member of staff employed to drive business development and progress commercial opportunities in the US
- In August we secured our first customer revenues from the US
- First US expo at ASHG Annual Meeting, Houston, Tx
- Additional events attended for partnership meetings and business development – AACC, AMP, JP Morgan

- Progress being made on strategy for market entry into China and Japan
## Strategic priorities for growth

<table>
<thead>
<tr>
<th>Organic</th>
<th>Inorganic</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Product penetration</strong></td>
<td><strong>M&amp;A</strong></td>
</tr>
<tr>
<td><em>Sell More in Existing Channels</em></td>
<td><em>Consolidator in the Market</em></td>
</tr>
<tr>
<td>Drive worldwide sales of NIPT, Cystic Fibrosis and other Reproductive Health products and services by targeting further expansion through direct and key distribution channels</td>
<td>Delivering integration benefits of the Elucigene acquisition, creating a strong platform for future M&amp;A activity</td>
</tr>
<tr>
<td><strong>Geographic expansion</strong></td>
<td><strong>Product expansion</strong></td>
</tr>
<tr>
<td><em>Sell into New Territories</em></td>
<td><em>New Product Lines and Content</em></td>
</tr>
<tr>
<td>Expand directly and through distributors into new geographies, including those opened up by Illumina licence agreement</td>
<td>Leverage our technical and regulatory expertise and partnerships to extend our genetic testing offering</td>
</tr>
<tr>
<td></td>
<td>Support diagnostic majors and bioinformatics specialists with IVD product contract development partnerships</td>
</tr>
<tr>
<td><strong>Inorganic</strong></td>
<td><strong>M&amp;A</strong></td>
</tr>
<tr>
<td></td>
<td>Considering additional selective synergistic M&amp;A opportunities</td>
</tr>
<tr>
<td></td>
<td>Fragmented market with minimal medium-sized entities, presents opportunity for consolidation</td>
</tr>
</tbody>
</table>
Investor Communications Update

- **Walbrook PR** appointed 1 August 2019 to handle all Media Relations & Investor Relations
  - *Proactive team specialising in growing AIM companies & Lifesciences focused*

- Register for YGEN investor updates on news, media / analyst commentary, investor access events, webcasts, video content and a regularly updated 2-page company summary
- Regular investor-access events planned to allow direct access to management
- Email yourgene@walbrookpr.com
- Increased Media engagement

- We understand the desire for news-flow however:
  - Highly competitive landscape
  - We have a broader product portfolio and customer base
  - But we are not in a position to announce every new customer win
  - Focus on strategic customer collaborations and new markets